[1]陈利军,任民柱,袁东方.调强放射治疗联合替吉奥治疗老年局部中晚期鼻咽癌临床疗效观察[J].新乡医学院学报,2017,34(6):532-534.[doi:10.7683/xxyxyxb.2017.06.022]
　CHEN Li-jun,REN Min-zhu,YUAN Dong-fang.Curative effect of intensity-modulated radiotherapy combined with tegafur，gimeracil and oteracil potassium capsule for treatment of elderly patients with localized advanced nasopharyngeal carcinoma[J].Journal of Xinxiang Medical University,2017,34(6):532-534.[doi:10.7683/xxyxyxb.2017.06.022]
点击复制

调强放射治疗联合替吉奥治疗老年局部中晚期鼻咽癌临床疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
34
期数:
2017年6
页码:
532-534
栏目:
临床研究
出版日期:
2017-06-05

文章信息/Info

Title:
Curative effect of intensity-modulated radiotherapy combined with tegafur，gimeracil and oteracil potassium capsule for treatment of elderly patients with localized advanced nasopharyngeal carcinoma
作者:
陈利军; 任民柱; 袁东方
（新乡市中心医院放疗科，河南　新乡　453000）
Author(s):
CHEN Li-jun; REN Min-zhu; YUAN Dong-fang
（Department of Radiotherapy，Xinxiang Central Hospital，Xinxiang 453000，Henan Province，China）
关键词:
替吉奥胶囊; 鼻咽癌; 调强放射治疗; 化学治疗
Keywords:
gegafur; gimeracil and oteracil porassium capsule; nasopharyngeal carcinoma; intensity-modulated radiotherapy; chemotherapy
分类号:
R739.6
DOI:
10.7683/xxyxyxb.2017.06.022
文献标志码:
A
摘要:
目的　观察调强放射治疗联合替吉奥治疗中晚期鼻咽癌的临床疗效及不良反应。方法　选取2011年1月至2015年8月新乡市中心医院收治的66例经病理组织学诊断为鼻咽部鳞状细胞癌Ⅲ~Ⅳa期患者，将患者随机分为单放组（32例）和同步组（34例）。单放组患者采用调强放射治疗，剂量为70~76 Gy；同步组患者在调强放射治疗基础上同步给予替吉奥胶囊60 mg·m-2，口服，每日2次，连服28 d，42 d为1个周期，放射治疗结束后继续化学治疗1个周期。2组患者在治疗后3个月、1 a行鼻咽部及颈部磁共振、纤维鼻咽镜、胸部CT、腹部彩色超声检查，观察患者的治疗效果及不良反应。结果　治疗后3个月，2组患者治疗均有效，无疾病进展患者，其中单放组患者完全缓解（CR）率为 59.38%（19/32），同步组患者CR率为88.24%（30/34），同步组患者CR率显著高于单放组（χ2=7.180，P<0.05）。治疗后1 a，单放组患者无病生存率59.38 %（19/32），低于同步组的73.53%（25/34）（χ2=5.552,P<0.05）；单放组患者总生存率为87.50 %（28/32），与同步组的91.18%（31/34）比较差异无统计学意义（χ2=0.036,P>0.05）。同步组患者口腔黏膜反应（χ2=4.484，P<0.05）、骨髓抑制（χ2=5.945，P<0.05）、胃肠道反应（χ2=4.890，P<0.05）发生率均显著高于单放组；2组患者皮肤反应发生率比较差异无统计学意义（χ2=0.194，P>0.05）。结论　调强放射治疗联合替吉奥治疗局部中晚期鼻咽癌疗效确切，不良反应可耐受。
Abstract:
Objective　To observe the clinical effect and adverse reaction of intensity-modulated radiotherapy（IMRT） combined with tegafur，gimeracil and oteracil potassium capsule for treatment of elderly patients with advanced nasopharyngeal carcinoma.Methods　Sixty-six patients who were diagnosed as nasopharyngeal carcinoma（squamous cell carcinoma，stage Ⅲ or Ⅳa） by histopathology in Xinxiang Central Hospital from January 2011 to August 2015 were selected and divided into IMRT group（n=32） and radiochemotherapy group（n=34）.The patients in the IMRT group were given IMRT（70-76 Gy）；based on this，the patients in radiochemotherapy group were given tegafur，gimeracil and oteracil potassium capsule（60 mg·m-2，two times per day） orally for 28 days，42 days was a cycle；when the radiotherapy finished，the patients continued to be treated with chemotherapy for one cycle.The treatment effect and the incidence of adverse reactions of patients in the two groups were observed by nasopharyngeal and neck nuclear magnetic resonance，fiber nasopharyngeal mirror，chest computed tomography and abdominal ultrasonography at three months and one year after the treatment.Results　At three months after treatment，all patients were effective，no patient was stable disease or progression of disease.The complete remission（CR） rate of patients in the IMRT group and radiochemotherapy group was 59.38%（19/32），88.24%（30/34） respectively；the CR rate of patients in the radiochemotherapy group was significantly higher than that in the IMRT group（χ2=7.180，P<0.05）.At one year after treatment，the disease-free survival rate of patients in the radiochemotherapy group［73.53%（25/34）］ was significantly higher than that in the IMRT group［59.38%（19/32）］ （χ2=5.552,P<0.05）.The overall survival rate of patients in the IMRT group and radiochemotherapy group was 87.50 %（28/32），91.18%（31/34） respectively；there was no statistic difference in the overall survival rate between the two groups（χ2=0.036,P>0.05）.The incidence of oral mucous reaction，myelosuppression and gastrointestinal reaction of patients in the radiochemotherapy group were significantly higher than those in IMRT group （χ2=4.484，5.945，4.890；P<0.05）.There was no significant difference in the incidence of skin reaction between the two groups （χ2=0.194，P>0.05）.Conclusion　IMRT combined with tegafur，gimeracil and oteracil potassium capsule chemotherapy for advanced nasopharyngeal carcinoma is effective and the toxicity can be tolerated.

参考文献/References:

［1］　陈绍俊，吴梦馨，韦晓谋，等.ERCC1 mRNA 表达水平与Ⅱ期鼻咽癌顺铂同步放化疗疗效相关性的临床研究［J］.肿瘤基础与临床，2016，29（5）：373-376.
［2］　洪梅，孙新臣，葛小林，等.调强适形放射治疗晚期前列腺癌的临床观察［J］.临床肿瘤学杂志，2009，14（11）：1015-1017.
［3］　易俊林，高黎，黄晓东，等.416例鼻咽癌调强放射治疗远期生存与影响因素分析［J］.中华放射肿瘤学杂志，2012，21（3）：196-199.
［4］　周际昌.实用肿瘤内科学［M］.2版.北京：人民卫生出版社，2003：645-649.
［5］　CHENG S H，TSAI S Y，YEN K L，et al.Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma［J］.J Clin Oncol，2000，18（10）：2040-2045.
［6］　LEE C C，CHU S T.Concurrent chemoradiotherapy with adjuvant chemotherapy for high-risk nasopharyngeal carcinoma［J］.Auris Nasus Larynx，2009，36（6）：688-694.
［7］　LIN J C，JAN J S，HSU C Y，et al.Phase 3 study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcionoma：positive effect on overall and progression-free survival［J］.J Clin Oncol，2003，21（4）：631-634.
［8］　丘文泽，黄培钰，施君理，等.调强放疗结合诱导化疗或同期加辅助化疗治疗局部晚期鼻咽癌的疗效比较［J］.中国肿瘤临床，2015，42（4）：231-235.
［9］　徐瑾，郝俊芳.局部晚期鼻咽癌放射治疗的研究进展［J］.中华肿瘤防治杂志，2011，18（2）：156-160.
［10］　艾茹玉，周娟，谢波.多西他赛与顺铂同步放化疗治疗局部晚期鼻咽癌的疗效观察［J］.临床肿瘤学杂志，2017，22（2）：147-151.
［11］　洪明晃，闵庆华，郭翔，等.从鼻咽癌分层综合治疗的结果来验证92分期的合理性［J］.癌症，2000，9（5）：462.
［12］　赵充，韩非，卢丽霞，等.调强适形放射治疗对局部晚期鼻咽癌的临床疗效［J］.癌症，2004，13（11）：1532-1537.
［13］　寇卫政，杨留中，褚秀峰，等.替吉奥联合塞来昔布治疗晚期胃癌疗效观察［J］.新乡医学院学报，2015，32（4）：336-339.
［14］　WEN L，YOU C，LU X.Phase II trial of concurrent chemoradiotherapy with S-1 versus weekly cisplatin for locoregionally advanced nasopharyngeal carcinoma［J］.Mol Clin Oncol，2015，3（3）：687-691.
［15］　HARADA K，FERDOUS T.Gimeracil exerts radiosensitizing effects on oral squamous cell carcinoma cells in vitro and in vivo［J］.Antican Res，2016，36（11）：5923-5930.

相似文献/References:

[1]武莉萍,杨留勤,张巍巍.鼻咽癌85例临床特征分析[J].新乡医学院学报,2002,19(04):318.
[2]林少俊,韩露,宗井凤,等.局部晚期鼻咽癌300例放射化学治疗远期效果分析[J].新乡医学院学报,2008,25(05):485.
[3]李栋才,杨贵,姚春苑.鼻咽癌组织中X 连锁凋亡抑制蛋白及caspase-3 和Smac /DIABLO的表达及意义[J].新乡医学院学报,2010,27(06):576.
[4]鲁保才,卢振民,张爱民,等.干扰性小核糖核酸靶向抑制趋化因子受体4基因表达对鼻咽癌细胞增殖和侵袭的影响[J].新乡医学院学报,2018,35(1):030.[doi:10.7683/xxyxyxb.2018.01.007]
　LU Bao-cai,LU Zhen-min,ZHANG Ai-min,et al.Effect of targeted inhibition of the expression of chemokine receptor 4 gene by small interfering RNA on the invasion and proliferation of nasopharyngeal carcinoma cells[J].Journal of Xinxiang Medical University,2018,35(6):030.[doi:10.7683/xxyxyxb.2018.01.007]
[5]杨琳红,王维峰,朱金玲,等.抑癌基因PTEN单核苷酸多态性与鼻咽癌的相关性[J].新乡医学院学报,2018,35(6):478.[doi:10.7683/xxyxyxb.2018.06.007]
　YANG Lin-hong,WANG Wei-feng,ZHU Jin-ling,et al.Correlation between single nucleotide polymorphisms of tumor suppressor gene PTEN and nasopharyngeal carcinoma[J].Journal of Xinxiang Medical University,2018,35(6):478.[doi:10.7683/xxyxyxb.2018.06.007]
[6]訾滢洁,王　彬,高会霞.糖蛋白96、Raf-1和Nei内切核酸酶Ⅷ样蛋白2表达与鼻咽癌患者放射治疗敏感性的相关性[J].新乡医学院学报,2022,39(6):548.[doi:10.7683/xxyxyxb.2022.06.010]
　ZI Yingjie,WANG Bin,GAO Huixia.Correlation between the expressions of glycoprotein 96,Raf-1 and Nei endonuclease Ⅷ-like 2 and the sensitivity to radiotherapy in patients with nasopharyngeal carcinoma[J].Journal of Xinxiang Medical University,2022,39(6):548.[doi:10.7683/xxyxyxb.2022.06.010]

更新日期/Last Update: 2017-06-05